RIGEL PHARMACEUTICALS INC (RIGL): Results of Operations and Financial Condition
RIGEL PHARMACEUTICALS INC (RIGL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 rigl-20260804xex991q22026r.htm EX-99.1 Document Exhibit 99.1 Rigel Reports Second Quarter 2026 Financial Results • Second quarter 2026 total revenues of $78.7 million, including net product sales of $67.0 million and contract revenues from collaborations of $11.7 millio
How this was made
The 30-second read
Why it matters
The filing provides concrete, time-bound catalysts (mid-August VEPPANU availability, Phase 1b dose expansion completion in 2H 2026, Phase 2 dose selection in 2H 2026) alongside updated full-year revenue guidance.
Market read
Traders get a fresh earnings-and-guidance datapoint plus a near-term commercialization date for a newly licensed FDA-approved product, which can drive short-term repricing.
What to watch
The guidance excludes VEPPANU net product sales and provides only a broad revenue range; traders may discount the impact until post-launch sales ramp and any additional regulatory/label updates.
Background
This is Rigel’s SEC 8-K (Item 2.02) with Q2 2026 financial results and business updates, including a VEPPANU PROTAC licensing deal and R289 clinical progress.
Ticker impact
Rigel reports Q2 2026 results and raises/updates 2026 outlook to $285 to $295 million, plus VEPPANU launch timing in mid-August.
Moderately positive bias into the mid-August VEPPANU availability window, with follow-through dependent on uptake and any incremental guidance changes.
The filing discloses multiple tradable datapoints: Q2 revenue and net income, updated full-year revenue range, upfront payment and effective licensing, and an expected mid-August commercial availability date.
Market effects
Reinforces investor focus on commercial-stage biotech profitability plus PROTAC differentiation and near-term launch execution.
Limited direct regional spillover; primarily US biotech sentiment.
International partner/regulatory progress (Brazil approval, Mexico launch, Japan NDA milestone) supports global commercialization narrative.
Counterpoint
Despite strong Q2 and guidance, the stock may already price in launch optimism; execution risk remains for VEPPANU uptake and R289 Phase 1b-to-Phase 2 transition.
Key entities
- companyRigel Pharmaceuticals, Inc.
Commercial-stage biotech reporting Q2 2026 results, updated 2026 revenue outlook, and VEPPANU launch timing.
- productVEPPANU (vepdegestrant)
FDA-approved PROTAC for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer; expected US commercial availability mid-August 2026.
- clinical_programR289
Dual IRAK1/4 inhibitor in Phase 1b for lower-risk MDS; dose expansion enrollment on track for 2H 2026 milestones.
- partnerArvinas, Inc.
Licensing partner for VEPPANU development, manufacturing, and commercialization agreement.
- partnerPfizer Inc.
Co-party in the VEPPANU licensing agreement; Rigel paid an upfront payment in Q2 2026.
